Statements (23)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:drug
|
| gptkbp:approvalYear |
1999
|
| gptkbp:approvedBy |
gptkb:FDA
|
| gptkbp:ATCCode |
N04BX02
|
| gptkbp:contraindication |
gptkb:liver_disease
|
| gptkbp:drugClass |
catechol-O-methyltransferase inhibitor
|
| gptkbp:eliminatedIn |
urine
|
| gptkbp:form |
gptkb:tablet
|
| gptkbp:genericName |
gptkb:entacapone
|
| gptkbp:halfLife |
0.4–0.7 hours
|
| https://www.w3.org/2000/01/rdf-schema#label |
Comtan
|
| gptkbp:increasesEffectOf |
gptkb:levodopa
|
| gptkbp:manufacturer |
gptkb:Novartis
|
| gptkbp:mechanismOfAction |
inhibits COMT enzyme
|
| gptkbp:pregnancyCategory |
C
|
| gptkbp:routeOfAdministration |
oral
|
| gptkbp:sideEffect |
nausea
diarrhea dyskinesia urine discoloration |
| gptkbp:usedFor |
gptkb:Parkinson's_disease
|
| gptkbp:bfsParent |
gptkb:NOVN
|
| gptkbp:bfsLayer |
5
|